Is ritonavir boosting associated with gout?

International Journal of STD and AIDS

Volumn 16, Issue 5, 2005, Pages 362-364

  Creighton, S ^a   Miller, R ^a,b   Edwards, S ^a   Copas, A ^b   French, P ^a  

^a Camden Primary Care Trust   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

GOUT; HIV; HYPERURICAEMIA; PROTEASE INHIBITORS

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RITONAVIR; SAQUINAVIR;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GOUT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; INCIDENCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

GOUT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERURICEMIA; INCIDENCE; RISK FACTORS; RITONAVIR;

EID: 18944406298     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462053888907     Document Type: Article

References (9)

1. Maesaka JK, Cusano AJ. Hypouricaemia in acquired immunodeficiency syndrome. Am J Kidney Dis 1991;17:724–5
2. Manfredi R, Chiodo F. Longitudinal assessment of serum urate levels as a marker of HIV disease progression. Int J STD AIDS 1998;9:433–4
3. Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials. J AIDS 1993;6:1212–1233
4. Disla E, Stein S, Acevedo M, Cuppari G. Gouty arthritis in the acquired immuno-deficiency syndrome: an unusual but aggressive case. Arthr Rheumat 1995;4:570–2
5. Mehlaff D, Stein DS. Gout secondary to ritonavir and didanosine. AIDS 1996;10:1744
6. Buscombe JR, Miller RF, Lui D, Ell PJ. Combined 67Ga citrate and 99Tcm-human immunoglobulin imaging in human immunodeficiency virus-positive patients with fever of undetermined origin. Nucl Med Commun 1991;12:583–592
7. Takahashi S, Moriwaki Y, Tsutsumi Z, Yamakita J, Yama-moto T, Hada T. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. Metabolism 2001;50:393–8
8. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403–2406
9. Carr A, Samaras K, Thorrisdottir A, et al. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093–2099